Legal & General Group PLC Alnylam Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 960,959 shares of ALNY stock, worth $226 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
960,959
Previous 960,959 -0.0%
Holding current value
$226 Million
Previous $264 Million -0.0%
% of portfolio
0.06%
Previous 0.06%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$233.81 - $287.01 $8.1 Million - $9.94 Million
34,629 Added 3.74%
960,959 $264 Million
Q2 2024

Aug 14, 2024
BUY
$143.31 - $247.0 $735,896 - $1.27 Million
5,135 Added 0.56%
926,330 $225 Million
Q1 2024

May 14, 2024
SELL
$146.51 - $198.2 $1.43 Million - $1.93 Million
-9,744 Reduced 1.05%
921,195 $138 Million
Q4 2023

Feb 15, 2024
BUY
$151.41 - $196.57 $20.6 Million - $26.8 Million
136,268 Added 17.15%
930,939 $178 Million
Q3 2023

Nov 14, 2023
SELL
$170.77 - $211.65 $634,922 - $786,914
-3,718 Reduced 0.47%
794,671 $141 Million
Q2 2023

Aug 14, 2023
BUY
$185.01 - $212.05 $12.5 Million - $14.3 Million
67,367 Added 9.22%
798,389 $152 Million
Q1 2023

May 15, 2023
SELL
$182.66 - $235.53 $243,485 - $313,961
-1,333 Reduced 0.18%
731,022 $146 Million
Q4 2022

Feb 14, 2023
SELL
$185.53 - $241.31 $4.11 Million - $5.34 Million
-22,137 Reduced 2.93%
732,355 $174 Million
Q3 2022

Nov 14, 2022
SELL
$138.54 - $232.0 $3.39 Million - $5.67 Million
-24,456 Reduced 3.14%
754,492 $151 Million
Q2 2022

Aug 22, 2022
BUY
$120.42 - $169.29 $2.59 Million - $3.64 Million
21,526 Added 2.84%
778,948 $114 Million
Q1 2022

May 16, 2022
BUY
$127.18 - $173.91 $9.9 Million - $13.5 Million
77,852 Added 11.46%
757,422 $124 Million
Q4 2021

Feb 14, 2022
BUY
$159.56 - $209.29 $2.04 Million - $2.68 Million
12,785 Added 1.92%
679,570 $115 Million
Q3 2021

Nov 15, 2021
SELL
$169.75 - $207.73 $2.82 Million - $3.45 Million
-16,625 Reduced 2.43%
666,785 $126 Million
Q2 2021

Aug 12, 2021
BUY
$128.63 - $176.89 $4.76 Million - $6.54 Million
36,972 Added 5.72%
683,410 $116 Million
Q1 2021

May 17, 2021
BUY
$126.83 - $175.69 $135,200 - $187,285
1,066 Added 0.17%
646,438 $91.3 Million
Q4 2020

Feb 12, 2021
BUY
$122.97 - $147.0 $1.79 Million - $2.14 Million
14,580 Added 2.31%
645,372 $83.9 Million
Q3 2020

Nov 13, 2020
SELL
$121.19 - $165.49 $276,797 - $377,979
-2,284 Reduced 0.36%
630,792 $91.8 Million
Q2 2020

Aug 14, 2020
BUY
$104.21 - $156.44 $3.07 Million - $4.61 Million
29,439 Added 4.88%
633,076 $93.8 Million
Q1 2020

May 14, 2020
BUY
$93.12 - $133.99 $2.75 Million - $3.96 Million
29,567 Added 5.15%
603,637 $65.7 Million
Q4 2019

Feb 13, 2020
BUY
$74.51 - $124.23 $3.04 Million - $5.07 Million
40,774 Added 7.65%
574,070 $66.1 Million
Q3 2019

Nov 13, 2019
BUY
$70.9 - $87.82 $2.29 Million - $2.84 Million
32,349 Added 6.46%
533,296 $42.9 Million
Q2 2019

Aug 14, 2019
BUY
$65.86 - $92.79 $1.74 Million - $2.45 Million
26,365 Added 5.56%
500,947 $36.3 Million
Q1 2019

May 15, 2019
BUY
$72.76 - $93.45 $7.83 Million - $10.1 Million
107,682 Added 29.35%
474,582 $44.3 Million
Q4 2018

Feb 15, 2019
BUY
$62.67 - $88.33 $1.69 Million - $2.38 Million
26,958 Added 7.93%
366,900 $26.8 Million
Q3 2018

Nov 20, 2018
SELL
$87.52 - $122.67 $49,798 - $69,799
-569 Reduced 0.17%
339,942 $29.8 Million
Q2 2018

Aug 10, 2018
SELL
$88.31 - $107.8 $711,690 - $868,760
-8,059 Reduced 2.31%
340,511 $33.5 Million
Q1 2018

May 17, 2018
BUY
$115.92 - $148.54 $28.1 Million - $36 Million
242,098 Added 227.38%
348,570 $41.5 Million
Q4 2017

Feb 13, 2018
BUY
$114.49 - $139.98 $12.2 Million - $14.9 Million
106,472
106,472 $13.5 Million

Others Institutions Holding ALNY

# of Institutions
641
Shares Held
109M
Call Options Held
1.28M
Put Options Held
1.21M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email